Peter F Orio 3rd
Overview
Explore the profile of Peter F Orio 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
347
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moningi S, Orio 3rd P
Int J Radiat Oncol Biol Phys
. 2025 Feb;
121(3):584.
PMID: 39909609
No abstract available.
2.
King M, Svatos M, Chell E, Pigrish V, Miller K, Low D, et al.
Pract Radiat Oncol
. 2023 Dec;
14(3):e214-e219.
PMID: 38043644
Purpose: Recently, a randomized trial demonstrated that a hyaluronic acid (HA) spacer placed before prostate hypofractionated intensity modulated radiation therapy improved rectal dosimetry and reduced acute grade 2+ gastrointestinal toxicity....
3.
Gejerman G, Goldstein M, Chao M, Shore N, Lederer J, Crawford E, et al.
Pract Radiat Oncol
. 2023 Sep;
14(1):e57-e61.
PMID: 37657504
No abstract available.
4.
Corkum M, Buyyounouski M, Chang A, Chung H, Chung P, Cox B, et al.
Radiother Oncol
. 2023 Apr;
184:109672.
PMID: 37059334
Background And Purpose: Local recurrences after previous radiotherapy (RT) are increasingly being identified in biochemically recurrent prostate cancer. Salvage prostate brachytherapy (BT) is an effective and well tolerated treatment option....
5.
Mariados N, Orio 3rd P, Schiffman Z, Van T, Engelman A, Nurani R, et al.
JAMA Oncol
. 2023 Feb;
9(4):511-518.
PMID: 36757690
Importance: Hypofractionated radiation therapy (RT) for prostate cancer has been associated with greater acute grade 2 gastrointestinal (GI) toxic effects compared with conventionally fractionated RT. Objective: To evaluate whether a...
6.
Boyce-Fappiano D, Nguyen K, Gjyshi O, Manzar G, Abana C, Klopp A, et al.
JCO Oncol Pract
. 2021 Sep;
17(12):e1958-e1967.
PMID: 34550749
Purpose: Cervical cancer (CC) disproportionately affects minorities who have higher incidence and mortality rates. Standard of care for locally advanced CC involves a multimodality approach including brachytherapy (BT), which independently...
7.
Mantz C, Thaker N, Pendyala P, Hubbard A, Eichler T, Shah C, et al.
JCO Oncol Pract
. 2021 Sep;
17(12):e1977-e1983.
PMID: 34529516
Purpose: The Radiation Oncology Alternative Payment Model (APM) is a Medicare demonstration project that will test whether prospective bundled payments to a randomly selected group of physician practices, hospital outpatient...
8.
Boyce-Fappiano D, Ning M, Gjyshi O, Mesko S, Pasalic D, Chang A, et al.
JCO Oncol Pract
. 2021 Jun;
17(12):761-764.
PMID: 34097458
No abstract available.
9.
Guthier C, Orio 3rd P, Buzurovic I, Cormack R
Med Phys
. 2021 Feb;
48(5):2108-2117.
PMID: 33586191
Purpose: Permanent low-dose-rate brachytherapy is a widely used treatment modality for managing prostate cancer. In such interventions, treatment planning can be a challenging task and requires experience and skills of...
10.
King M, Muralidhar V, Yang D, Mouw K, Martin N, DAmico A, et al.
Brachytherapy
. 2020 Nov;
20(1):1-9.
PMID: 33129714
Purpose: The role of multimodality therapy (MMT) in the treatment of Gleason 8-10 prostate cancer remains controversial. We sought to evaluate factors associated with MMT utilization for primary radical prostatectomy...